Stage III Non–Small-Cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment

INTRODUCTION: Outcome data from Cancer Care Ontario suggest that only 27% of patients with stage III non-small-cell lung cancer (NSCLC) receive chemoradiotherapy. However, many patients are not suitable for radical treatment. This study aimed to determine the proportion of patients with stage III NSCLC suitable for radical treatment and to examine reasons for choosing a palliative approach otherwise. PATIENTS AND METHODS: This was a …